The last decade has seen the introduction of several new chemotherapeutic agents that
have activity against non-small cell lung cancer (NSCLC) and produce single-agent …

In recent years, advances in molecular diagnostics have transformed the management of
advanced non-small-cell lung cancer (NSCLC), allowing for increasingly personalized …

The role of chemotherapy in the treatment of non-small cell lung cancer has increased
greatly over the past few years. One of the main reasons for the increased acceptance of …

Improvements in drug development and clinical trial design have resulted in a wider range
of treatment options for patients with advanced non-small cell lung cancer (NSCLC) …

Recent advances in methods of genomic profiling have accelerated our understanding of
the biology of oncologic diseases. Accumulating evidence suggests that both histology and …

With rare exceptions, attempts to combine so-called targeted agents with standard cytotoxic
chemotherapy in advanced non–small cell lung cancer have yielded disappointing results …

As a result of improved effectiveness of first-, second-line and maintenance therapeutic
regimens in non-small cell lung cancer, there is need for new options as third-line treatment …

The management of patients with advanced non-small-cell lung cancer (NSCLC) is
becoming increasingly complex, with the identification of driver mutations/rearrangements …

N on-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide,
although evidence now suggests that novel biological agents could improve survival of …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …